Related references
Note: Only part of the references are listed.Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura
Spero R. Cataland et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs
Hans Ulrichts et al.
BLOOD (2011)
Investigational drugs in thrombotic thrombocytopenic purpura
Patrizia Noris et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura
Petra Jilma-Stohlawetz et al.
THROMBOSIS AND HAEMOSTASIS (2011)
How I treat patients with thrombotic thrombocytopenic purpura: 2010
James N. George
BLOOD (2010)
Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus)
Hendrik B. Feys et al.
BLOOD (2010)
Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779
J. L. Diener et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease
Simon F. De Meyer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences
HB Feys et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons
DM Wu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Share Paper
